Client News

Mainz Biomed provides year-end 2022 corporate review

Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Destiny Pharma announces year end Trading Update Good progress across all key projects in 2022

InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19

Abivax receives FDA agreement on pediatric development plan with obefazimod in IBD

Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Rentschler Biopharma awarded Chiesi Supplier Award

Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform

Carbios publishes first Sustainability Report and underscores commitment to circularity and environmental responsibilities

ABIVAX TO ATTEND THE J.P. MORGAN 41ST ANNUAL HEALTHCARE CONFERENCE